Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study

This article has no abstract
Epistemonikos ID: 8b5a6d8409c2515a1e0b9a089429ae9a69e19d53
First added on: Feb 12, 2025